Heart Test Laboratories (HSCS) announced that the Centers for Medicare & Medicaid Services, CMS, has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System, OPPS, final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences’ MyoVista wavECGTM algorithm and MyoVista Insights low ejection fraction algorithm, upon FDA clearance. The payment rate is expected to be $125.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSCS:
- 3 Penny Stocks to Watch Now, 9/25/24